Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Commencing Out-of-Bed Rehabilitation in Critical Care-What Influences Clinical Decision-Making?

Berney SC, Rose JW, Denehy L, Granger CL, Ntoumenopoulos G, Crothers E, Steel B, Clarke S, Skinner EH.

Arch Phys Med Rehabil. 2019 Feb;100(2):261-269.e2. doi: 10.1016/j.apmr.2018.07.438. Epub 2018 Aug 30.

PMID:
30172644
2.

Optimal dietary patterns designed from local foods to achieve maternal nutritional goals.

Raymond J, Kassim N, Rose JW, Agaba M.

BMC Public Health. 2018 Apr 4;18(1):451. doi: 10.1186/s12889-018-5369-x.

3.

Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis.

Rose JW, Giovannoni G, Wiendl H, Gold R, Havrdová E, Kappos L, Selmaj KW, Zhao J, Riester K, Tsao LC, Greenberg SJ.

Mult Scler Relat Disord. 2017 Oct;17:32-40. doi: 10.1016/j.msard.2017.06.006. Epub 2017 Jun 19.

PMID:
29055471
4.

Context-specific food-based approach for ensuring nutrition security in developing countries: a review.

Raymond J, Kassim N, Rose JW, Agaba M.

Int J Food Sci Nutr. 2018 Jun;69(4):410-416. doi: 10.1080/09637486.2017.1373751. Epub 2017 Sep 13.

PMID:
28903614
5.

Analysis of nutritional adequacy of local foods for meeting dietary requirements of children aged 6-23 months in rural central Tanzania.

Raymond J, Agaba M, Mollay C, Rose JW, Kassim N.

Arch Public Health. 2017 Aug 17;75:60. doi: 10.1186/s13690-017-0226-4. eCollection 2017.

6.

Optimal formulations of local foods to achieve nutritional adequacy for 6-23-month-old rural Tanzanian children.

Raymond J, Kassim N, Rose JW, Agaba M.

Food Nutr Res. 2017 Jul 30;61(1):1358035. doi: 10.1080/16546628.2017.1358035. eCollection 2017.

7.

Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.

Baldassari LE, Rose JW.

Neurotherapeutics. 2017 Oct;14(4):842-858. doi: 10.1007/s13311-017-0553-8. Review.

8.

Low Levels of Physical Activity During Critical Illness and Weaning: The Evidence-Reality Gap.

Connolly BA, Mortimore JL, Douiri A, Rose JW, Hart N, Berney SC.

J Intensive Care Med. 2017 Jan 1:885066617716377. doi: 10.1177/0885066617716377. [Epub ahead of print]

PMID:
28675113
9.

Characterization of spinal cord white matter by suppressing signal from hindered space. A Monte Carlo simulation and an ex vivo ultrahigh-b diffusion-weighted imaging study.

Sapkota N, Yoon S, Thapa B, Lee Y, Bisson EF, Bowman BM, Miller SC, Shah LM, Rose JW, Jeong EK.

J Magn Reson. 2016 Nov;272:53-59. doi: 10.1016/j.jmr.2016.09.001. Epub 2016 Sep 4.

PMID:
27635467
10.

Characteristics of Children and Adolescents With Multiple Sclerosis.

Belman AL, Krupp LB, Olsen CS, Rose JW, Aaen G, Benson L, Chitnis T, Gorman M, Graves J, Harris Y, Lotze T, Ness J, Rodriguez M, Tillema JM, Waubant E, Weinstock-Guttman B, Casper TC; US Network of Pediatric MS Centers.

Pediatrics. 2016 Jul;138(1). pii: e20160120. doi: 10.1542/peds.2016-0120.

11.

Two-dimensional single-shot diffusion-weighted stimulated EPI with reduced FOV for ultrahigh-b radial diffusion-weighted imaging of spinal cord.

Sapkota N, Shi X, Shah LM, Bisson EF, Rose JW, Jeong EK.

Magn Reson Med. 2017 Jun;77(6):2167-2173. doi: 10.1002/mrm.26302. Epub 2016 Jun 14.

PMID:
27296165
12.

Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report.

Chitnis T, Ness J, Krupp L, Waubant E, Hunt T, Olsen CS, Rodriguez M, Lotze T, Gorman M, Benson L, Belman A, Weinstock-Guttman B, Aaen G, Graves J, Patterson M, Rose JW, Casper TC.

Neurology. 2016 Jan 19;86(3):245-52. doi: 10.1212/WNL.0000000000002283. Epub 2015 Dec 18.

13.

Retinal nerve fiber layer sector-specific compromise in relapsing and remitting multiple sclerosis.

Loughran-Fjeldstad AS, Carlson NG, Husebye CD, Cook LJ, Rose JW.

eNeurologicalSci. 2015 Oct 9;1:30-37. doi: 10.1016/j.ensci.2015.09.004. eCollection 2015 Jun.

14.

The role of the prostaglandin E2 receptors in vulnerability of oligodendrocyte precursor cells to death.

Carlson NG, Bellamkonda S, Schmidt L, Redd J, Huecksteadt T, Weber LM, Davis E, Wood B, Maruyama T, Rose JW.

J Neuroinflammation. 2015 May 23;12:101. doi: 10.1186/s12974-015-0323-7.

15.

Prospective observation of physical activity in critically ill patients who were intubated for more than 48 hours.

Berney SC, Rose JW, Bernhardt J, Denehy L.

J Crit Care. 2015 Aug;30(4):658-63. doi: 10.1016/j.jcrc.2015.03.006. Epub 2015 Mar 13.

PMID:
25813549
16.

Protective environmental factors for neuromyelitis optica.

Graves J, Grandhe S, Weinfurtner K, Krupp L, Belman A, Chitnis T, Ness J, Weinstock-Guttman B, Gorman M, Patterson M, Rodriguez M, Lotze T, Aaen G, Mowry EM, Rose JW, Simmons T, Casper TC, James J, Waubant E; US Network of Pediatric Multiple Sclerosis Centers.

Neurology. 2014 Nov 18;83(21):1923-9. doi: 10.1212/WNL.0000000000001001. Epub 2014 Oct 22.

17.

The US Network of Pediatric Multiple Sclerosis Centers: Development, Progress, and Next Steps.

Casper TC, Rose JW, Roalstad S, Waubant E, Aaen G, Belman A, Chitnis T, Gorman M, Krupp L, Lotze TE, Ness J, Patterson M, Rodriguez M, Weinstock-Guttman B, Browning B, Graves J, Tillema JM, Benson L, Harris Y; US Network of Pediatric Multiple Sclerosis Centers.

J Child Neurol. 2015 Sep;30(10):1381-7. doi: 10.1177/0883073814550656. Epub 2014 Sep 30.

18.

Advances in the management of neurogenic detrusor overactivity in multiple sclerosis.

Yonnet GJ, Fjeldstad AS, Carlson NG, Rose JW.

Int J MS Care. 2013 Summer;15(2):66-72. doi: 10.7224/1537-2073.2012-031.

19.

Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis.

Sheridan JP, Robinson RR, Rose JW.

Expert Rev Clin Pharmacol. 2014 Jan;7(1):9-19. doi: 10.1586/17512433.2014.865516. Epub 2013 Dec 2.

PMID:
24308792
20.

Resveratrol exacerbates both autoimmune and viral models of multiple sclerosis.

Sato F, Martinez NE, Shahid M, Rose JW, Carlson NG, Tsunoda I.

Am J Pathol. 2013 Nov;183(5):1390-1396. doi: 10.1016/j.ajpath.2013.07.006. Epub 2013 Oct 1.

21.

Optical coherence tomography as a biomarker in multiple sclerosis.

Fjeldstad AS, Carlson NG, Rose JW.

Expert Opin Med Diagn. 2012 Nov;6(6):593-604. doi: 10.1517/17530059.2012.719496. Epub 2012 Aug 23.

PMID:
23480840
22.

Vitamin D as a clinical biomarker in multiple sclerosis.

Carlson NG, Rose JW.

Expert Opin Med Diagn. 2013 May;7(3):231-42. doi: 10.1517/17530059.2013.772978. Epub 2013 Feb 19. Review.

PMID:
23480560
23.

Cell-based reporter gene assay for therapy-induced neutralizing antibodies to interferon-beta in multiple sclerosis.

Martins TB, Rose JW, Gardiner GL, Kusukawa N, Husebye D, Hill HR.

J Interferon Cytokine Res. 2013 Feb;33(2):52-7. doi: 10.1089/jir.2012.0027. Epub 2012 Nov 15.

PMID:
23153300
24.

Anti-CD25 immunotherapy: regulating the regulators.

Rose JW.

Sci Transl Med. 2012 Aug 1;4(145):145fs25. doi: 10.1126/scitranslmed.3004440. No abstract available.

PMID:
22855460
25.

Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis.

Langer HF, Choi EY, Zhou H, Schleicher R, Chung KJ, Tang Z, Göbel K, Bdeir K, Chatzigeorgiou A, Wong C, Bhatia S, Kruhlak MJ, Rose JW, Burns JB, Hill KE, Qu H, Zhang Y, Lehrmann E, Becker KG, Wang Y, Simon DI, Nieswandt B, Lambris JD, Li X, Meuth SG, Kubes P, Chavakis T.

Circ Res. 2012 Apr 27;110(9):1202-10. doi: 10.1161/CIRCRESAHA.111.256370. Epub 2012 Mar 27.

26.

Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay.

Martins TB, Rose JW, Jaskowski TD, Wilson AR, Husebye D, Seraj HS, Hill HR.

Am J Clin Pathol. 2011 Nov;136(5):696-704. doi: 10.1309/AJCP7UBK8IBVMVNR.

PMID:
22031307
27.

Vascular function and multiple sclerosis.

Fjeldstad AS, McDaniel J, Witman MA, Ives SJ, Zhao J, Rose JW, Hannon J, Wray DW, Richardson RS.

J Neurol. 2011 Nov;258(11):2036-42. doi: 10.1007/s00415-011-6065-2. Epub 2011 May 5.

PMID:
21544565
28.

Clinical biomarkers in multiple sclerosis.

Rose JW, Carlson NG.

Expert Opin Med Diagn. 2011 May;5(3):213-26. doi: 10.1517/17530059.2011.562498. Epub 2011 Mar 29.

PMID:
23484499
29.

Using diffusion tensor imaging and immunofluorescent assay to evaluate the pathology of multiple sclerosis.

Zollinger LV, Kim TH, Hill K, Jeong EK, Rose JW.

J Magn Reson Imaging. 2011 Mar;33(3):557-64. doi: 10.1002/jmri.22502.

30.

Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death.

Carlson NG, Rojas MA, Redd JW, Tang P, Wood B, Hill KE, Rose JW.

J Neuroinflammation. 2010 Apr 13;7:25. doi: 10.1186/1742-2094-7-25.

31.

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.

Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW; CHOICE investigators.

Lancet Neurol. 2010 Apr;9(4):381-90. doi: 10.1016/S1474-4422(10)70033-8. Epub 2010 Feb 15. Erratum in: Lancet Neurol. 2010 Aug;9(8):759. Wadinger, K [corrected to Wandinger, K].

PMID:
20163990
32.

Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases.

Brettschneider J, Jaskowski TD, Tumani H, Abdul S, Husebye D, Seraj H, Hill HR, Fire E, Spector L, Yarden J, Dotan N, Rose JW.

J Neuroimmunol. 2009 Dec 10;217(1-2):95-101. doi: 10.1016/j.jneuroim.2009.07.017. Epub 2009 Oct 30.

PMID:
19879655
33.

Cerebellar Purkinje cells incorporate immunoglobulins and immunotoxins in vitro: implications for human neurological disease and immunotherapeutics.

Hill KE, Clawson SA, Rose JW, Carlson NG, Greenlee JE.

J Neuroinflammation. 2009 Oct 29;6:31. doi: 10.1186/1742-2094-6-31.

34.

Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.

Rojas MA, Carlson NG, Miller TL, Rose JW.

Ther Adv Neurol Disord. 2009 Sep;2(5):291-7. doi: 10.1177/1756285609337992.

35.

Multiple sclerosis: evidence of maternal effects and an increasing incidence in women.

Rose JW.

Neurology. 2009 Aug 25;73(8):578-9. doi: 10.1212/WNL.0b013e3181b529c6. Epub 2009 Jul 29. No abstract available.

PMID:
19641171
36.

Monoclonal antibody treatments for multiple sclerosis.

Rose JW, Foley JF, Carlson NG.

Curr Treat Options Neurol. 2009 May;11(3):211-20.

PMID:
19364456
37.

Recurrent granuloma annulare during treatment with daclizumab.

Mehta LR, Rose JW.

Mult Scler. 2009 Apr;15(4):527-8. doi: 10.1177/1352458508101324. No abstract available.

PMID:
19324986
38.

Microglial inhibition of neuroprotection by antagonists of the EP1 prostaglandin E2 receptor.

Carlson NG, Rojas MA, Black JD, Redd JW, Hille J, Hill KE, Rose JW.

J Neuroinflammation. 2009 Feb 17;6:5. doi: 10.1186/1742-2094-6-5.

39.

Monoclonal antibody treatments for multiple sclerosis.

Rose JW, Foley J, Carlson N.

Curr Neurol Neurosci Rep. 2008 Sep;8(5):419-26. Review.

PMID:
18713579
40.

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.

Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG.

Neurology. 2007 Aug 21;69(8):785-9.

PMID:
17709711
41.

Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens.

Burt RK, Marmont A, Oyama Y, Slavin S, Arnold R, Hiepe F, Fassas A, Snowden J, Schuening F, Myint H, Patel DD, Collier D, Heslop H, Krance R, Statkute L, Verda L, Traynor A, Kozak T, Hintzen RQ, Rose JW, Voltarelli J, Loh Y, Territo M, Cohen BA, Craig RM, Varga J, Barr WG.

Arthritis Rheum. 2006 Dec;54(12):3750-60. Review. No abstract available.

42.

Immunohistochemical evidence of inducible nitric oxide synthase and nitrotyrosine in a case of clinically isolated optic neuritis.

Tsoi VL, Hill KE, Carlson NG, Warner JE, Rose JW.

J Neuroophthalmol. 2006 Jun;26(2):87-94.

PMID:
16845306
43.

Antioxidants in multiple sclerosis: do they have a role in therapy?

Carlson NG, Rose JW.

CNS Drugs. 2006;20(6):433-41. Review.

PMID:
16734496
44.

The pathologic role for COX-2 in apoptotic oligodendrocytes in virus induced demyelinating disease: implications for multiple sclerosis.

Carlson NG, Hill KE, Tsunoda I, Fujinami RS, Rose JW.

J Neuroimmunol. 2006 May;174(1-2):21-31. Epub 2006 Mar 3.

PMID:
16516308
45.

Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody.

Rose JW, Watt HE, White AT, Carlson NG.

Ann Neurol. 2004 Dec;56(6):864-7.

PMID:
15499632
46.
47.

Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.

Mehrotra MM, Heath JA, Smyth MS, Pandey A, Rose JW, Seroogy JM, Volkots DL, Nannizzi-Alaimo L, Park GL, Lambing JL, Hollenbach SJ, Scarborough RM.

J Med Chem. 2004 Apr 8;47(8):2037-61.

PMID:
15056002
48.

Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion.

Rose JW, Hill KE, Watt HE, Carlson NG.

J Neuroimmunol. 2004 Apr;149(1-2):40-9.

PMID:
15020063
49.

Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial.

Johnson KP, Brooks BR, Ford CC, Goodman AD, Lisak RP, Myers LW, Pruitt AA, Rizzo MA, Rose JW, Weiner LP, Wolinsky JS.

Mult Scler. 2003 Dec;9(6):585-91.

PMID:
14664471
50.

Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.

Pandey A, Volkots DL, Seroogy JM, Rose JW, Yu JC, Lambing JL, Hutchaleelaha A, Hollenbach SJ, Abe K, Giese NA, Scarborough RM.

J Med Chem. 2002 Aug 15;45(17):3772-93.

PMID:
12166950

Supplemental Content

Support Center